CoChat
Sign Up
Cited by 735Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchHealth Promotion and Cardiovascular Prevention

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?

Stern, Michael P., Williams, Ken, González-Villalpando, Clicerio, Hunt, Kelly J., Haffner, Steven M.·2004·Diabetes Care
DOI 10.2337/diacare.27.11.2676
Open this paper in CoChat — free account

Abstract

OBJECTIVE—The metabolic syndrome has been promoted as a method for identifying high-risk individuals for type 2 diabetes and cardiovascular disease (CVD). We therefore sought to compare this syndrome, as defined by the National Cholesterol Education Program, to the Diabetes Predicting Model and the Framingham Risk Score as predictors of type 2 diabetes and CVD, respectively. RESEARCH DESIGN AND METHODS—A population-based sample of 1,709 initially nondiabetic San Antonio Heart Study (SAHS) participants were followed for 7.5 years, 195 of whom developed type 2 diabetes. Over the same time interval, 156 of 2,570 SAHS participants experienced a cardiovascular event. A population-based sample of 1,353 initially nondiabetic Mexico City Diabetes Study (MCDS) participants were followed for 6.5 years, 125 of whom developed type 2 diabetes. Baseline measurements included medical history, age, sex, ethnicity, smoking status, BMI, blood pressure, fasting and 2-h plasma glucose levels, and fasting serum total and HDL cholesterol and triglycerides. RESULTS—The sensitivities for predicting diabetes with the metabolic syndrome were 66.2 and 62.4% in the SAHS and the MCDS, respectively, and the false-positive rates were 27.8 and 38.7%, respectively. The sensitivity and false-positive rates for predicting CVD with the metabolic syndrome in the SAHS were 67.3 and 34.2%, respectively. At corresponding false-positive rates, the two predicting models had significantly higher sensitivities and, at corresponding sensitivities, significantly lower false-positive rates than the metabolic syndrome for both end points. Combining the metabolic syndrome with either predicting model did not improve the prediction of either end point. CONCLUSIONS—The metabolic syndrome is inferior to established predicting models for either type 2 diabetes or CVD.

Overview

Integrity signals

Registry

Crossref · 10.2337/diacare.27.11.2676

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

Sorted by citations

Items 601–700 of 733

Related

See all

Metadata

Authors
Stern, M. P., Williams, K., González-Villalpando, C., Hunt, K. J., & Haffner, S. M.
Affiliations
  • Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas
  • The University of Texas at San Antonio Health Science Center (US)
  • Centro de Estudios en Diabetes, The American British Cowdray Hospital and Unidades de Investigación Médica en Enfermedades Metabólicas y Epidemiología Clínica, Hospital Gabriel Mancera, Instituto Mexicano del Seguro Social, Mexico City, Mexico
ORCID
Hunt, Kelly J.
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2004-11-01
Volume
27
Issue
11
Pages
2676-2681
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.27.11.2676
OpenAlex
W1975366890
Cited by
735
References
17
Citations by year
2026: 5 · 2025: 10 · 2024: 19 · 2023: 15 · 2022: 19 · 2021: 21 · 2020: 13 · 2019: 24 · 2018: 29 · 2017: 33 · 2016: 35 · 2015: 48 · 2014: 39 · 2013: 40 · 2012: 43
FWCI
31.54
Type
journal article
Language
en
Update notices
correction (2005-01-01)
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL024799, R01HL036820)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
metabolic syndrome, type 2 diabetes, cardiovascular disease, risk prediction, Framingham risk score, sensitivity and false positive rate, San Antonio Heart Study, risk stratification
MeSH terms
Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, False Positive Reactions, Female, Humans, Male, Middle Aged, Models, Biological, Predictive Value of Tests, Risk, Likelihood Functions, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review